ASMB
Assembly Biosciences Inc
NASDAQ · Biotechnology
$26.22
+0.83 (+3.27%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 75.13M | 45.30M | 303.48M | 300.07M | 309.84M |
| Net Income | -105,834,062 | -57,438,735 | 8.79M | 8.49M | 9.09M |
| EPS | — | — | — | — | — |
| Profit Margin | -140.9% | -133.8% | 2.9% | 2.8% | 2.9% |
| Rev Growth | +65.8% | +65.8% | +10.9% | +3.4% | +15.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 140.38M | 138.81M | 136.47M |
| Total Equity | — | — | 194.17M | 166.11M | 184.14M |
| D/E Ratio | — | — | 0.72 | 0.84 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -119,305,520 | -68,347,249 | 16.60M | 15.38M | 17.46M |
| Free Cash Flow | — | — | 12.57M | 12.77M | 10.54M |